Polo-like kinase and its inhibitors: Ready for the match to start?
Publication/Presentation Date
11-1-2015
Abstract
Polo-like kinases (Plks) plays a central role in the normal cell cycle and their upregulation has been shown to play a role in the pathogenesis of multiple human cancers. Preclinical work demonstrates that targeting Plk has a significant impact on the treatment of both solid and hematologic malignancies in vitro and in vivo. We review here the basic science and clinical work to date with the Plks as well as future directions with this novel class of mitotic inhibitors.
Volume
90
Issue
11
First Page
1071
Last Page
1076
ISSN
1096-8652
Published In/Presented At
Palmisiano, N. D., & Kasner, M. T. (2015). Polo-like kinase and its inhibitors: Ready for the match to start?. American journal of hematology, 90(11), 1071–1076. https://doi.org/10.1002/ajh.24177
Disciplines
Medicine and Health Sciences
PubMedID
26294255
Department(s)
Hematology-Medical Oncology Division
Document Type
Article